- Home
- CPIX vs BTAI Comparison
CPIX vs BTAI Comparison
Compare CPIX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPIX
- BTAI
- Stock Information
- Founded
- CPIX 1999
- BTAI 2017
- Country
- CPIX United States
- BTAI United States
- Employees
- CPIX N/A
- BTAI N/A
- Industry
- CPIX Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- CPIX Health Care
- BTAI Health Care
- Exchange
- CPIX Nasdaq
- BTAI Nasdaq
- Market Cap
- CPIX 51.5M
- BTAI 48.3M
- IPO Year
- CPIX 2009
- BTAI 2018
- Fundamental
- Price
- CPIX $3.30
- BTAI $2.18
- Analyst Decision
- CPIX
- BTAI Buy
- Analyst Count
- CPIX 0
- BTAI 5
- Target Price
- CPIX N/A
- BTAI $32.80
- AVG Volume (30 Days)
- CPIX 31.2K
- BTAI 1.0M
- Earning Date
- CPIX 11-04-2025
- BTAI 11-13-2025
- Dividend Yield
- CPIX N/A
- BTAI N/A
- EPS Growth
- CPIX N/A
- BTAI N/A
- EPS
- CPIX N/A
- BTAI N/A
- Revenue
- CPIX $42,071,813.00
- BTAI $868,000.00
- Revenue This Year
- CPIX N/A
- BTAI N/A
- Revenue Next Year
- CPIX N/A
- BTAI $614.78
- P/E Ratio
- CPIX N/A
- BTAI N/A
- Revenue Growth
- CPIX 11.34
- BTAI N/A
- 52 Week Low
- CPIX $1.04
- BTAI $1.17
- 52 Week High
- CPIX $7.25
- BTAI $13.28
- Technical
- Relative Strength Index (RSI)
- CPIX 47.07
- BTAI 36.88
- Support Level
- CPIX $3.41
- BTAI $2.14
- Resistance Level
- CPIX $3.54
- BTAI $2.46
- Average True Range (ATR)
- CPIX 0.19
- BTAI 0.18
- MACD
- CPIX -0.02
- BTAI 0.01
- Stochastic Oscillator
- CPIX 23.60
- BTAI 5.49
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.